CFTR and lung disorder: Regression analyses for ppFEV1 gains revealed that after 3 months of ETI therapy, age and ppFEV1 at ETI initiation were significantly associated with ppFEV1 gains (p < 0.001 and p = 0.004, respectively), while neither gender, prior CFTR modulator therapy, nor BMI or degree of lung disease severity at baseline was associated with this outcome.